γδ T cells in HIV disease: Past, present, and future

Frontiers in Immunology

Volumn 6, Issue JAN, 2015, Pages

  David Pauza, C ^a   Poonia, Bhawna ^a   Li, Haishan ^a   Cairo, Cristiana ^a   Chaudhry, Suchita ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gamma delta T cell; HIV; Immunotherapy; Vdelta1 gamma delta T cells; Vgamma9Vdelta2 T cells

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR; CYTOKINE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; RANTES; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN FUNCTION; CELLULAR IMMUNITY; GAMMA DELTA T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84926651093     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00687     Document Type: Review

References (106)

1. Moir S, Fauci AS. B-cell exhaustion in HIV infection: the role of immune activation. Curr Opin HIV AIDS (2014) 9:472-7. doi:10.1097/COH.0000000000000092.
2. Kottilil S, Jackson JO, Reitano KN, O'shea MA, Roby G, Lloyd M, et al. Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr (2007) 46:151-9. doi:10.1097/QAI.0b013e3180dc9909.
3. Autran B, Triebel F, Katlama C, Rozenbaum W, Hercend T, Debre P. T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 75:206-10.
4. De Paoli P, Gennari D, Martelli P, Basaglia G, Crovatto M, Battistin S, et al. A subset of gamma delta lymphocytes is increased during HIV-1 infection. Clin Exp Immunol (1991) 83:187-91. doi:10.1111/j.1365-2249.1991.tb05612.x.
5. Margolick JB, Scott ER, Odaka N, Saah AJ. Flow cytometric analysis of gamma delta T cells and natural killer cells in HIV-1 infection. Clin Immunol Immunopathol (1991) 58:126-38. doi:10.1016/0090-1229(91)90154-3.
6. De Maria A, Ferrazin A, Ferrini S, Ciccone E, Terragna A, Moretta L. Selective increase of a subset of T cell receptor gamma delta T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J Infect Dis (1992) 165:917-9. doi:10.1093/infdis/165.5.917.
7. Harris LD, Klatt NR, Vinton C, Briant JA, Tabb B, Ladell K, et al. Mechanisms underlying gammadelta T-cell subset perturbations in SIV-infected Asian rhesus macaques. Blood (2010) 116:4148-57. doi:10.1182/blood-2010-05-283549.
8. Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S, et al. Engagement of NKp30 on Vdelta1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood (2012) 119:4013-6. doi:10.1182/blood-2011-11-390153.
9. Fausther-Bovendo H, Wauquier N, Cherfils-Vicini J, Cremer I, Debre P, Vieillard V. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. AIDS (2008) 22:217-26. doi:10.1097/QAD.0b013e3282f46e7c.
10. Sindhu ST, Ahmad R, Morisset R, Ahmad A, Menezes J. Peripheral blood cytotoxic gammadelta T lymphocytes from patients with human immunodeficiency virus type 1 infection and AIDS lyse uninfected CD4+ T cells, and their cytocidal potential correlates with viral load. J Virol (2003) 77:1848-55. doi:10.1128/JVI.77.3.1848-1855.2003.
11. Hermier F, Comby E, Delaunay A, Petitjean J, Favennec L, Bazin C, et al. Decreased blood TcR gamma delta+ lymphocytes in AIDS and p24-antigenemic HIV-1-infected patients. Clin Immunol Immunopathol (1993) 69:248-50. doi:10.1006/clin.1993.1176.
12. Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, et al. HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses (2003) 19:21-9. doi:10.1089/08892220360473934.
13. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis (2004) 189:1482-6. doi:10.1086/382961.
14. Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, Jacobson LP, et al. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol (2008) 128:349-57. doi:10.1016/j.clim.2008.04.008.
15. Boullier S, Cochet M, Poccia F, Gougeon ML. CDR3-independent gamma delta V delta 1+ T cell expansion in the peripheral blood of HIV-infected persons. J Immunol (1995) 154:1418-31.
16. Hinz T, Wesch D, Friese K, Reckziegel A, Arden B, Kabelitz D. T cell receptor gamma delta repertoire in HIV-1-infected individuals. Eur J Immunol (1994) 24:3044-9. doi:10.1002/eji.1830241219.
17. Agostini C, Zambello R, Trentin L, Cerutti A, Bulian P, Crivellaro C, et al. Gamma delta T cell receptor subsets in the lung of patients with HIV-1 infection. Cell Immunol (1994) 153:194-205. doi:10.1006/cimm.1994.1017.
18. Kabelitz D, Bender A, Schondelmaier S, Schoel B, Kaufmann SH. A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J Exp Med (1990) 171:667-79. doi:10.1084/jem.171.3.667.
19. De Libero G, Casorati G, Giachino C, Carbonara C, Migone N, Matzinger P, et al. Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells. J Exp Med (1991) 173:1311-22. doi:10.1084/jem.173.6.1311.
20. Davodeau F, Peyrat MA, Hallet MM, Gaschet J, Houde I, Vivien R, et al. Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J Immunol (1993) 151:1214-23.
21. Davodeau F, Peyrat MA, Hallet MM, Houde I, Vie H, Bonneville M. Peripheral selection of antigen receptor junctional features in a major human gamma delta subset. Eur J Immunol (1993) 23:804-8. doi:10.1002/eji.1830230405.
22. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science (1994) 264:267-70. doi:10.1126/science.8146660.
23. Schoel B, Sprenger S, Kaufmann SH. Phosphate is essential for stimulation of V gamma 9V delta 2 T lymphocytes by mycobacterial low molecular weight ligand. Eur J Immunol (1994) 24:1886-92. doi:10.1002/eji.1830240826.
24. Burk MR, Mori L, De Libero G. Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol (1995) 25:2052-8. doi:10.1002/eji.1830250737.
25. Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity (1995) 3:495-507. doi:10.1016/1074-7613(95)90178-7.
26. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature (1995) 375:155-8. doi:10.1038/375155a0.
27. Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med (1990) 171:1597-612. doi:10.1084/jem.171.5.1597.
28. Cairo C, Armstrong CL, Cummings JS, Deetz CO, Tan M, Lu C, et al. Impact of age, gender, and race on circulating gammadelta T cells. Hum Immunol (2010) 71:968-75. doi:10.1016/j.humimm.2010.06.014.
29. Harly C, Guillaume Y, Nedellec S, Peigne CM, Monkkonen H, Monkkonen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood (2012) 120:2269-79. doi:10.1182/blood-2012-05-430470.
30. Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, et al. The molecular basis for modulation of human Vgamma9Vdelta2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem (2012) 287:32780-90. doi:10.1074/jbc. M112.384354.
31. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol (2013) 14:908-16. doi:10.1038/ni.2665.
32. Wang H, Henry O, Distefano MD, Wang YC, Raikkonen J, Monkkonen J, et al. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vgamma2Vdelta2 T cells. J Immunol (2013) 191:1029-42. doi:10.4049/jimmunol.1300658.
33. Decaup E, Duault C, Bezombes C, Poupot M, Savina A, Olive D, et al. Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVgamma9+ gammadelta T lymphocytes. Immunol Lett (2014) 161:133-7. doi:10.1016/j.imlet.2014.05.011.
34. Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells. Immunity (2014) 40:490-500. doi:10.1016/j.immuni.2014.03.003.
35. Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol (1996) 157:449-61.
36. Wallace M, Scharko AM, Pauza CD, Fisch P, Imaoka K, Kawabata S, et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med (1997) 3:60-71.
37. Chervenak KA, Lederman MM, Boom WH. Bacterial antigen activation of Vdelta1 and Vdelta2 gammadelta T cells of persons infected with human immunodeficiency virus type 1. J Infect Dis (1997) 175:429-33. doi:10.1093/infdis/175.2.429.
38. Grottrup-Wolfers E, Grunewald T, Strzelecki R, Pohle HD, Ruf B. Selective expansion of gammadelta T cells among liver-derived lymphocytes of AIDS patients with disseminated Mycobacterium avium complex infection. Clin Immunol Immunopathol (1997) 85:151-7. doi:10.1006/clin.1997.4410.
39. Agrati C, D'offizi G, Narciso P, Selva C, Pucillo LP, Ippolito G, et al. Gammadelta T cell activation by chronic HIV infection may contribute to intrahepatic vdelta1 compartmentalization and hepatitis C virus disease progression independent of highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2001) 17:1357-63. doi:10.1089/08892220152596614.
40. Rossol R, Dobmeyer JM, Dobmeyer TS, Klein SA, Rossol S, Wesch D, et al. Increase in Vdelta1+ gammadelta T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. Br J Haematol (1998) 100:728-34. doi:10.1046/j.1365-2141.1998.00630.x.
41. Karunakaran MM, Gobel TW, Starick L, Walter L, Herrmann T. Vgamma9 and Vdelta2 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (Vicugna pacos). Immunogenetics (2014) 66:243-54. doi:10.1007/s00251-014-0763-8.
42. Wallace M, Gan YH, Pauza CD, Malkovsky M. Antiviral activity of primate gamma delta T lymphocytes isolated by magnetic cell sorting. J Med Primatol (1994) 23:131-5. doi:10.1111/j.1600-0684.1994.tb00113.x.
43. Gan YH, Pauza CD, Malkovsky M. Gamma delta T cells in rhesus monkeys and their response to simian immunodeficiency virus (SIV) infection. Clin Exp Immunol (1995) 102:251-5. doi:10.1111/j.1365-2249.1995.tb03773.x.
44. Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, Malkovsky M. Gamma delta T lymphocyte responses to HIV. Clin Exp Immunol (1996) 103:177-84. doi:10.1046/j.1365-2249.1996.d01-625.x.
45. Boismenu R, Feng L, Xia YY, Chang JC, Havran WL. Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J Immunol (1996) 157:985-92.
46. Tikhonov I, Deetz CO, Paca R, Berg S, Lukyanenko V, Lim JK, et al. Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES. Int Immunol (2006) 18:1243-51. doi:10.1093/intimm/dxl055.
47. Poccia F, Battistini L, Cipriani B, Mancino G, Martini F, Gougeon ML, et al. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis (1999) 180:858-61. doi:10.1086/314925.
48. Lehner T, Mitchell E, Bergmeier L, Singh M, Spallek R, Cranage M, et al. The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol (2000) 30:2245-56. doi:10.1002/1521-4141(2000)30:8<2245::AID-IMMU2245>3.0.CO;2-7.
49. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: strong expression of CCR5 is a selective feature of V delta 2/V gamma 9 gamma delta T cells. J Immunol (2002) 168:4920-9. doi:10.4049/jimmunol.168.10.4920.
50. Poonia B, Pauza CD. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy (2012) 14:173-81. doi:10.3109/14653249.2011.623693.
51. Biswas P, Ferrarini M, Mantelli B, Fortis C, Poli G, Lazzarin A, et al. Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. Eur J Immunol (2003) 33:252-63. doi:10.1002/immu.200390028.
52. Fenoglio D, Zocchi MR, Parodi A, Durando P, Gabutitp G, Gasparini R, et al. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. J Prev Med Hyg (2011) 52:137-41.
53. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M, et al. Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood (2009) 113:6611-8. doi:10.1182/blood-2009-01-198028.
54. Kabelitz D, Pechhold K, Bender A, Wesselborg S, Wesch D, Friese K, et al. Activation and activation-driven death of human gamma/delta T cells. Immunol Rev (1991) 120:71-88. doi:10.1111/j.1600-065X.1991.tb00588.x.
55. Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, Pauza CD. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology (2001) 104:19-27. doi:10.1046/j.1365-2567.2001.01282.x.
56. Hebbeler AM, Cairo C, Cummings JS, Pauza CD. Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother (2007) 56:819-29. doi:10.1007/s00262-006-0235-6.
57. van 't Wout AB, Lehrman GK, Mikheeva SA, O'keeffe GC, Katze MG, Bumgarner RE, et al. Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol (2003) 77:1392-402. doi:10.1128/JVI.77.2.1392-1402.2003.
58. van 't Wout AB, Swain JV, Schindler M, Rao U, Pathmajeyan MS, Mullins JI, et al. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol (2005) 79:10053-8. doi:10.1128/JVI.79.15.10053-10058.2005.
59. Imlach S, Leen C, Bell JE, Simmonds P. Phenotypic analysis of peripheral blood gammadelta T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo. Virology (2003) 305:415-27. doi:10.1006/viro.2002.1759.
60. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 9:301-9. doi:10.1038/ni1566.
61. Cicala C, Martinelli E, Mcnally JP, Goode DJ, Gopaul R, Hiatt J, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 106:20877-82. doi:10.1073/pnas.0911796106.
62. Li H, Pauza CD. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS. Blood (2011) 118:5824-31. doi:10.1182/blood-2011-05-356535.
63. Li H, Pauza CD. The alpha4beta7 integrin binds HIV envelope but does not mediate bystander killing of gammadelta T cells. Blood (2012) 120:698-9. doi:10.1182/blood-2012-03-420117.
64. Biswas P, Mantelli B, Sica A, Malnati M, Panzeri C, Saccani A, et al. Expression of CD4 on human peripheral blood neutrophils. Blood (2003) 101:4452-6. doi:10.1182/blood-2002-10-3056.
65. Schnittman SM, Denning SM, Greenhouse JJ, Justement JS, Baseler M, Kurtzberg J, et al. Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. Proc Natl Acad Sci U S A (1990) 87:7727-31. doi:10.1073/pnas.87.19.7727.
66. Gurney KB, Yang OO, Wilson SB, Uittenbogaart CH. TCR gamma delta+ and CD161+ thymocytes express HIV-1 in the SCID-hu mouse, potentially contributing to immune dysfunction in HIV infection. J Immunol (2002) 169:5338-46. doi:10.4049/jimmunol.169.9.5338.
67. Li H, Peng H, Ma P, Ruan Y, Su B, Ding X, et al. Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis (2008) 46:1466-72. doi:10.1086/587107.
68. Li H, Chaudhry S, Poonia B, Shao Y, Pauza CD. Depletion and dysfunction of Vgamma2Vdelta2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol (2013) 10:42-9. doi:10.1038/cmi.2012.50.
69. Schenkel AR, Uno H, Pauza CD. Asymptomatic simian immunodeficiency virus infection decreases blood CD4(+) T cells by accumulating recirculating lymphocytes in the lymphoid tissues. J Virol (1999) 73:601-7.
70. Chaudhry S, Cairo C, Venturi V, Pauza CD. The gammadelta T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy. AIDS (2013) 27:1557-62. doi:10.1097/QAD.0b013e3283611888.
71. Quigley MF, Greenaway HY, Venturi V, Lindsay R, Quinn KM, Seder RA, et al. Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire. Proc Natl Acad Sci U S A (2010) 107:19414-9. doi:10.1073/pnas.1010586107.
72. Venturi V, Quigley MF, Greenaway HY, Ng PC, Ende ZS, Mcintosh T, et al. A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing. J Immunol (2011) 186:4285-94. doi:10.4049/jimmunol.1003898.
73. Greenaway HY, Ng B, Price DA, Douek DC, Davenport MP, Venturi V. NKT and MAIT invariant TCRalpha sequences can be produced efficiently by VJ gene recombination. Immunobiology (2013) 218:213-24. doi:10.1016/j.imbio.2012.04.003.
74. Boudova S, Li H, Sajadi MM, Redfield RR, Pauza CD. Impact of persistent HIV replication on CD4 negative Vgamma2Vdelta2 T cells. J Infect Dis (2012) 205:1448-55. doi:10.1093/infdis/jis217.
75. Urban EM, Li H, Armstrong C, Focaccetti C, Cairo C, Pauza CD. Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC Immunol (2009) 10:50. doi:10.1186/1471-2172-10-50.
76. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS (2007) 21:517-9. doi:10.1097/QAD.0b013e328013d9eb.
77. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, Redfield RR, et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS (2009) 23:1955-64. doi:10.1097/QAD.0b013e32832ff1ff.
78. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 3:e46. doi:10.1371/journal.ppat.0030046.
79. Martini F, Paglia MG, Montesano C, Enders PJ, Gentile M, Pauza CD, et al. V gamma 9V delta 2 T-cell anergy and complementarity-determining region 3-specific depletion during paroxysm of nonendemic malaria infection. Infect Immun (2003) 71:2945-9. doi:10.1128/IAI.71.5.2945-2949.2003.
80. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 342:921-9. doi:10.1056/NEJM200003303421303.
81. Ripamonti D, Hill A, Lauthouwers E, Van Delft Y, Moecklinghoff C. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment-any impact of residual viremia on treatment success? AIDS Rev (2013) 15:230-6.
82. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, et al. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 171:1567-79. doi:10.1084/jem.171.5.1567.
83. Fisch P, Kovats S, Fundim N, Sturm E, Braakman E, Demars R, et al. Function and specificity of human V gamma 9/V delta 2 T lymphocytes. Curr Top Microbiol Immunol (1991) 173:179-82.
84. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science (2005) 309:264-8. doi:10.1126/science.1110267.
85. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940.
86. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood (2010) 116:1726-33. doi:10.1182/blood-2009-07-234211.
87. Cairo C, Surendran N, Harris KM, Mazan-Mamczarz K, Sakoda Y, Diaz-Mendez F, et al. Vgamma2Vdelta2 T cell costimulation increases NK cell killing of monocyte-derived dendritic cells. Immunology (2014). doi:10.1111/imm.12386.
88. Patel RV, Weinberg JM. Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis. Cutis (2008) 82:117-22.
89. Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis (2010) 10:470-8. doi:10.1016/S1473-3099(10)70101-8.
90. Scotet E, Nedellec S, Devilder MC, Allain S, Bonneville M. Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk. Front Biosci (2008) 13:6872-85. doi:10.2741/3195.
91. Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gammadelta T lymphocytes. Blood (2011) 118:2743-51. doi:10.1182/blood-2011-01-328526.
92. Riedel DJ, Mwangi EI, Fantry LE, Alexander C, Hossain MB, Pauza CD, et al. High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS (2013) 27:1109-17. doi:10.1097/QAD.0b013e32835dc068.
93. Mavilio D, Lombardo G, Kinter A, Fogli M, La Sala A, Ortolano S, et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 203:2339-50. doi:10.1084/jem.20060894.
94. Reitano KN, Kottilil S, Gille CM, Zhang X, Yan M, O'shea MA, et al. Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection. AIDS Res Hum Retroviruses (2009) 25:1029-37. doi:10.1089/aid.2008.0311.
95. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 33:2410-8. doi:10.1002/eji.200324141.
96. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 102:2886-91. doi:10.1073/pnas.0409872102.
97. Zhang R, Xu J, Hong K, Yuan L, Peng H, Tang H, et al. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status. AIDS (2007) 21(Suppl 8):S9-17. doi:10.1097/01.aids.0000304691.32014.19.
98. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood (2009) 114:3822-30. doi:10.1182/blood-2009-06-226332.
99. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol (2010) 88:1119-30. doi:10.1189/jlb.0410225.
100. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, et al. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther (2008) 8:875-83. doi:10.1517/14712598.8.7.875.
101. Dieli F, Caccamo N, Meraviglia S. Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr Opin Investig Drugs (2008) 9:1089-94.
102. Caccamo N, Dieli F, Meraviglia S, Guggino G, Salerno A. Gammadelta T cell modulation in anticancer treatment. Curr Cancer Drug Targets (2010) 10:27-36. doi:10.2174/156800910790980188.
103. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 161:290-7. doi:10.1111/j.1365-2249.2010.04167.x.
104. Kalyan S, Wesch D, Kabelitz D. Aminobisphosphonates and toll-like receptor ligands: recruiting Vgamma9Vdelta2 T cells for the treatment of hematologic malignancy. Curr Med Chem (2011) 18:5206-16. doi:10.2174/092986711798184280.
105. Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol (2013) 160:123-32. doi:10.1111/bjh.12090.
106. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS (2009) 23:555-65. doi:10.1097/QAD.0b013e3283244619.